Revisiting the Genomic and Transcriptomic Landscapes from Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine.

Aims: Gynaecological malignancies such as breast, ovarian and cervical cancers have become an important public health problem. Detection of molecular alterations in cancer research is fundamental since it can reveal specific pathogenic patterns and genes that could serve as markers. Our aim was to characterize common genomic and transcriptomic signatures for the three gynaecologic malignancies with the highest incidence and mortality to try to identify new molecular markers, therapeutic targets and molecular signatures.

[Laparoscopic radical hysterectomy with lymphatic mapping and sentinel lymph node biopsy in early cervical cancer].

Background: in patients with early-stage cervical cancer (FIGO IA, IB2 and IIA), the incidence of lymph node metastases is up to 15%; the majority of early cervical cancer patients with pelvic and para-aortic lymphadenectomy does not benefit with the procedure and are at risk of associated morbidity (linfocyst, lymphedema, vascular or nerve damage).

Objective: To describe the experience and usefulness of lymphatic mapping and sentinel lymph node with total laparoscopic radical hysterectomy in early stage cervical cancer.

Patients And Method: Retrospective study in patients with diagnosis of cervical cancer in early stage, submitted to laparoscopic radical hysterectomy with lymphatic mapping and sentinel lymph node biopsy.

[Laparoscopy for staging and treatment of cervical cancer].

Background: Laparoscopic surgery for cervical cancer (CC) study and treatment is one of the main achievements in last years.

Objective: Describe the feasibility and experience of laparoscopic procedures for CC staging and treatment.

Patients And Method: A retrospective analysis of 75 patients with CC in different stages was done, group I included CC in situ patients treated with type I Piver hysterectomy, in group 2, patients with early CC treated with type II or III radical hysterectomy with pelvic lymphadenectomy and para-aortic lymph node sampling, and group 3 patients with locally advanced CC submitted to pelvic and para-aortic lymphadenectomy.